| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
sales@dcchemicals.com |
| Products Intro: |
Product Name:ARD-2128
CAS:2222111-87-5
Purity:98% HPLC Package:100mg，250mg，1g
|
|
| | ARD-2128 Basic information |
| Product Name: | ARD-2128 | | Synonyms: | ARD-2128;orally,ARD2128,AR-regulated,bioavailable,inhibit,ARD 2128,Inhibitor,prostate,Androgen Receptor,cancer,ARD-2128,tumor,PROTACs;Benzamide, N-[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-4-[4-[[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-4-piperidinyl]methyl]-1-piperazinyl]- | | CAS: | 2222111-87-5 | | MF: | C45H50ClN7O6 | | MW: | 820.37 | | EINECS: | | | Product Categories: | | | Mol File: | 2222111-87-5.mol |  |
| | ARD-2128 Chemical Properties |
| Boiling point | 1000.4±65.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 10.83±0.40(Predicted) | | color | Light yellow to green yellow |
| | ARD-2128 Usage And Synthesis |
| Biological Activity | ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer[1].
ARD-2128 is highly potent and effective in the inhibition of cell growth in the VCaP cell line and LNCaP cell line with the IC50 values of 4 nM and 5 nM, respectively[1].ARD-2128 (1, 10, 100, and 1000 nM; 24 hours) effectively reduces the AR protein level by >50% at 1 nM and achieves the AR degradation of >90% at 10, 100, and 1000 nM, respectively, in VCaP cell[1].
ARD-2128 (20 mg/kg; p.o.; once) is effective in reducing the level of AR protein in mice after 24 hours[1].ARD-2128 (10-40 mg/kg; p.o.; daily for 21 days) shows antitumor activity in the VCaP xenograft model in mice[1].ARD-2128 (5mg/kg; p.o.) treatment shows the Cmax, AUC0-t and t1/2 values of 1304 ng/mL, 22361 ng h/mL and 18.8 hours, respectively[1]. | | References | [1]. Han X, et al. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer [published online ahead of print, 2021 Aug 25]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00882. |
| | ARD-2128 Preparation Products And Raw materials |
|